

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
VIRTUAL PLATFORM**

October 20, 2021

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for July 14, 2021 meeting
- IV. Review of draft meeting summary for July 14, 2021 meeting
- V. Secretary's report
- VI. Old Business
  - A. Review of updated PA denials report for ALL plans
- VII. New Business
  - A. Addendum for Duchenne Muscular Dystrophy drugs protocol
  - B. Proposed protocol for Aduhelm<sup>®</sup> (aducanumab-avwa)
  - C. Proposed protocol for Bronchitol<sup>®</sup> (mannitol)
  - D. Proposed protocol for Imcivree<sup>®</sup> (setmelanotide)
  - E. Proposed exclusion protocol for Stromectol<sup>®</sup> (ivermectin)
- VIII. DURB Annual Report for SFY 2021 (Board members only)
- IX. A. Informational Highlights/Reports
  - 1. DXC Technology/NJ HMO 2<sup>nd</sup> Quarter 2021 Prior Authorization Report
  - 2. Summary of DURB Action Items
  - 3. (a) DHS, DHSS and MCO Programs Top Drugs Report/Physicians Administered Drugs (by amount paid and by category)
  - (b) Antiviral drugs by amount paid
- B. Medication information:
  - 1. COVID-19 Vaccines information  
<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>
  - 2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19  
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html> Continuously updated.
  - 3. New Jersey COVID-19 Information Hub (continuously updated)  
<https://covid19.nj.gov/>

4. Monoclonal Antibody Therapy for COVID-19 in New Jersey  
[https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=EAIaIQobChMI6v7fD28AIVi8CGCh3jjQQVEAAYASAAEgLggvD\\_BwE](https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=EAIaIQobChMI6v7fD28AIVi8CGCh3jjQQVEAAYASAAEgLggvD_BwE)
5. Lilly COVID-19 Antibody Therapies Access Update: Limitations of Authorized Use Modified by FDA. A list of states, territories, and U.S. jurisdictions in which bamlanivimab and etesevimab are and are not currently authorized is available on the following FDA website:  
<https://www.fda.gov/media/151719/download>

X. Referenced Materials:

- A. Protocol for biologic response modifier products used in plaque psoriasis – approved July 2021
- B. Protocol for Cabenuva® (cabotegravir/rilpivirine) – approved July 2021